[Aminoglutethimide in the treatment of advanced prostatic cancer].
A total of ten previously castrated men with stage D carcinoma received 1000 mg aminoglutethimide and 50 mg/die cortisoneacetate. The patients were evaluated using the criteria of the National Prostate Cancer Project. No patients showed objective response, three patients had reduction of bone pain and subjective improvement. Pretreatment testosterone, prolactine and estradiol levels were measured. Three patients had a statistically significant elevation of testosterone levels.
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D002369:Castration; D003131:Combined Modality Therapy; D004958:Estradiol / Q000097:blood; D045166:Estradiol Congeners / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011388:Prolactin / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000556:secondary*; D013739:Testosterone / Q000097:blood
D045166:Estradiol Congeners; D000616:Aminoglutethimide; D013739:Testosterone; D004958:Estradiol; D011388:Prolactin; D000135:Acid Phosphatase
Aminoglutethimid zur Behandlung des fortgeschrittenen Prostatakarzinoms.